Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502088 | 0.88 | AR (0.59) | ARSLC6A3SLC6A4KCNH2SLC22A12 | |
| SCHEMBL4188121 | 0.88 | AR (0.60) | ARSLC6A3SLC6A4KCNH2SLC22A12 | |
| SCHEMBL13890526 | 0.84 | AR (0.49) | ARSLC6A3SLC6A4KCNH2SLC6A2 | |
| SCHEMBL4188051 | 0.84 | AR (0.56) | ARSLC6A3SLC6A4KCNH2SLC22A12 | |
| SCHEMBL4183157 | 0.81 | AR (0.73) | ARSLC6A3SLC6A4KCNH2SLC22A12 | |
| SCHEMBL4168825 | 0.81 | AR (1.00) | ARSLC6A3SLC6A4KCNH2SLC6A2 | |
| SCHEMBL5503503 | 0.81 | AR (0.56) | ARSLC6A3SLC6A4KCNH2SLC22A12 | |
| SCHEMBL4179470 | 0.81 | AR (0.63) | ARSLC6A3SLC6A4KCNH2SLC22A12 | |
| SCHEMBL4168094 | 0.80 | AR (0.56) | ARSLC6A3SLC6A4KCNH2SLC22A12 | |
| SCHEMBL4374224 | 0.79 | AR (0.57) | ARSLC6A3SLC6A4KCNH2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | claimed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1781280-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018723-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885SLC6A3 3395/4885SLC6A4 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.